undamentalytics Newsletter
Sign in

20/20 Biolabs, Inc. cash flow statement

In fiscal 2025, 20/20 Biolabs, Inc.'s operations generated −$1.9m of cash.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Cash from operations−2,599−1,920
Depreciation and amortisation11663
Stock-based pay2,176516

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 20/20 Biolabs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 20/20 Biolabs, Inc.